SCHEMBL1102903

SCHEMBL1102903

c1ccc2c(c1)CCc1ccccc1N2c1c2ccccc2c(N2c3ccccc3CCc3ccccc32)c2ncccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
HTT P42858 4/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
POLB P06746 2/20 0.43
KMT2A Q03164 2/20 0.43
ALOX12 P18054 2/20 0.43
ALDH1A1 P00352 2/20 0.43
USP2 O75604 1/20 0.43
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 2/20 0.36
OPRK1 P41145 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSP90AA1 P07900 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102977 0.90 HTT (0.38) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1103075 0.86 MAPT (0.39) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1103242 0.81 TSHR (0.40) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1103025 0.81 KDM4E (0.37) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1102797 0.81 HTT (0.38) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1103192 0.79 TSHR (0.37) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1102983 0.79 KMT2A (0.40) HTTLMNAL3MBTL1POLBKMT2A
SCHEMBL1102901 0.79 HTT (0.38) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1102902 0.77 L3MBTL1 (0.36) KDM4EHTTLMNAMAPTL3MBTL1
SCHEMBL1102807 0.77 HSP90AA1 (0.36) KDM4EHTTLMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885HTT 4390/4885LMNA 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.